Dr Lal Pathlabs Ltd News
Dividend stocks: LIC, Asian Paints, 28 others to remain in focus next week
Dividend stocks: CARE Ratings, Supreme Industries, Sona BLW Precision Forgings, and Allied Blenders and Distillers are among the companies that will go ex-dividend next week
 "Dividend stocks: LIC, Asian Paints, 28 others to remain in focus next week")
Dr Lal PathLabs soars 11%, hits 52-week high on huge volumes; here's why
Care Ratings expects Dr Lal PathLabs' revenue to grow by 11-12 per cent per annum in the near-to-medium term driven by organic demand growth, its expanding geographical presence and new initiatives.
 "Dr Lal PathLabs soars 11%, hits 52-week high on huge volumes; here's why")
Healthcare stocks shine in weak market; Metropolis, Thyrocare jump upto 14%
Metropolis Healthcare share hit a 52-week high of ₹574.45, surging 14 per cent in trade. Thyrocare soared 12 per cent to ₹526.10, while Vijaya Diagnostic Centre gained 7 per cent to ₹1,298.45.
 "Healthcare stocks shine in weak market; Metropolis, Thyrocare jump upto 14%")
Dr Lal PathLabs hits 20% upper band on strong Q4; brokerages stay positive
Dr. Lal PathLabs recorded a 16.6 per cent Y-o-Y rise in revenue from operations to ₹702 crore in Q4 FY26 from ₹659.8 crore in the year-ago period
 "Dr Lal PathLabs hits 20% upper band on strong Q4; brokerages stay positive")
Dr Lal PathLabs Q4FY26 results: Net profit falls 15%; revenue rises 16.6%
Diagnostics firm reports profit decline due to prior-year tax benefit, while revenue growth remains strong on higher sample volumes and improved test mix
 "Dr Lal PathLabs Q4FY26 results: Net profit falls 15%; revenue rises 16.6%")
Dr Lal Path Labs Q4 FY26 results: Profit down 15.5%, revenue up 16.6%
Consolidated net profit fell to 1.31 billion rupees ($13.8 million) in the quarter ended March, from 1.55 billion rupees a year earlier
Diagnostics stocks favoured on Q4 optimism amid strong volume growth
Sector to outshine healthcare peers as higher volumes, steady realisations will boost revenue and profit, say analysts
 "Diagnostics stocks favoured on Q4 optimism amid strong volume growth")
Dr Lal PathLabs Q3 net profit falls 6.4% on new labour code impact
Diagnostics major reports a one-time charge linked to new labour codes even as revenue rose over 10% on higher sample volumes and network expansion
Dr Lal Path Labs Q3 results: PAT dips to ₹90.5 cr on labour code changes
The country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes
HDFC Sec turns bullish on Dr Lal PathLabs; upgrades to 'Buy'; raises target
Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares
 "HDFC Sec turns bullish on Dr Lal PathLabs; upgrades to 'Buy'; raises target")